LLY has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
LLY has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Eli Lilly and Co's average Accounts Payable for the three months ended in Sep. 2024 was $2,906 Mil. Eli Lilly and Co's Cost of Goods Sold for the three months ended in Sep. 2024 was $2,171 Mil. Hence, Eli Lilly and Co's Days Payable for the three months ended in Sep. 2024 was 122.14.
The historical rank and industry rank for Eli Lilly and Co's Days Payable or its related term are showing as below:
During the past 13 years, Eli Lilly and Co's highest Days Payable was 125.76. The lowest was 81.79. And the median was 99.69.
Eli Lilly and Co's Days Payable increased from Sep. 2023 (120.42) to Sep. 2024 (122.14). It may suggest that Eli Lilly and Co delayed paying its suppliers.
The historical data trend for Eli Lilly and Co's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eli Lilly and Co Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Days Payable | Get a 7-Day Free Trial | 100.98 | 100.25 | 81.79 | 99.13 | 116.72 |
Eli Lilly and Co Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Days Payable | Get a 7-Day Free Trial | 120.42 | 128.45 | 138.29 | 113.49 | 122.14 |
For the Drug Manufacturers - General subindustry, Eli Lilly and Co's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Eli Lilly and Co's Days Payable distribution charts can be found below:
* The bar in red indicates where Eli Lilly and Co's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Eli Lilly and Co's Days Payable for the fiscal year that ended in Dec. 2023 is calculated as
Days Payable (A: Dec. 2023 ) | |||||||||
= | Average Accounts Payable | / | Cost of Goods Sold | * | Days in Period | ||||
= | ( (Accounts Payable (A: Dec. 2022 ) | + | Accounts Payable (A: Dec. 2023 )) | / | count ) | / | Cost of Goods Sold (A: Dec. 2023 ) | * | Days in Period |
= | ( (1930.6 | + | 2598.8) | / | 2 ) | / | 7082.2 | * | 365 |
= | 2264.7 | / | 7082.2 | * | 365 | ||||
= | 116.72 |
Eli Lilly and Co's Days Payable for the quarter that ended in Sep. 2024 is calculated as:
Days Payable (Q: Sep. 2024 ) | |||||||||
= | Average Accounts Payable | / | Cost of Goods Sold | * | Days in Period | ||||
= | ( (Accounts Payable (Q: Jun. 2024 ) | + | Accounts Payable (Q: Sep. 2024 )) | / | count ) | / | Cost of Goods Sold (Q: Sep. 2024 ) | * | Days in Period |
= | ( (2924.8 | + | 2886.5) | / | 2 ) | / | 2170.8 | * | 365 / 4 |
= | 2905.65 | / | 2170.8 | * | 365 / 4 | ||||
= | 122.14 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Eli Lilly and Co's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.
Lilly Endowment Inc | 10 percent owner | 2801 NORTH MERIDIAN ST, INDIANAPOLIS IN 46208 |
Donald A Zakrowski | officer: Chief Accounting Officer | LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285 |
Johna Norton | officer: Senior VP, Global Quality | LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285 |
Alonzo Weems | officer: SVP, ERM & CECO | LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285 |
Patrik Jonsson | officer: SVP and Pres., Lilly Bio-Meds | LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285 |
Anne E. White | officer: SVP & Pres-Lilly Oncology | LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285 |
Eric Dozier | officer: EVP, HR & Diversity | LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285 |
Jackson P Tai | director | |
Mary Lynne Hedley | director | C/O TESARO, INC., 1000 WINTER ST., STE 3300, WALTHAM MA 02451 |
Marschall S Runge | director | LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285 |
Naarden Jacob Van | officer: SVP, CEO LoxoONC, Pres LlyONC | C/O ELI LILLY & CO, LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285 |
Diogo Rau | officer: SVP & CIDO | LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285 |
Edgardo Hernandez | officer: SVP & Pres., Mfg. Operations | LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285 |
Kimberly H Johnson | director | C/O FANNIE MAE, 1100 15TH STREET, NW, WASHINGTON DC 20005 |
Anat Ashkenazi | officer: SVP & CFO | LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285 |
From GuruFocus
By PRNewswire • 08-16-2024
By GuruFocus Research • 08-08-2024
By PRNewswire • 08-16-2024
By PRNewswire • 09-10-2024
By GuruFocus Research • 08-02-2024
By Sydnee Gatewood • 08-12-2024
By PRNewswire • 07-02-2024
By PRNewswire • 08-08-2024
By PRNewswire • 09-09-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.